Background/Aims: Guanidinoacetic acid (GAA) is an experimental nutritional additive under the functional group amino acids and derivatives, yet its use in human nutrition is hindered by limited data on GAA safety. In this double blind, placebo-controlled pilot study, we evaluated the effects of dietary GAA (3 g/day) administered for 2 weeks on the oxidant-antioxidant system in healthy men. Methods: Twelve healthy men (age 22.3 ± 2.1 years) were recruited for blood sampling at baseline (day 0) and at the end of the intervention period (day 14). Fasting venous blood samples were assessed for plasma total antioxidant capacity, superoxide dismutase (SOD), glutathione peroxidase, total oxidant status and malondialdehyde. Results: Fasting plasma SOD increased significantly from before to after administration in GAA-supplemented participants (91.4 ± 19.6 vs. 122.8 ± 25.9 ng/ml; p = 0.04). Other markers of oxidant-antioxidant system were not affected by the placebo or GAA intervention (p > 0.05). Conclusions: Oral GAA did not impact the cumulative action of antioxidants present in plasma, yet its SOD-boosting capacity might be considered beneficial when GAA is used as a dietary supplement. Further studies are needed to reveal the direct effects of GAA ingestion on markers of lipid and protein oxidation and on DNA damage.

1.
Baker DH: Advances in protein-amino acid nutrition of poultry. Amino Acids 2009;37:29-41.
2.
Sotgia S, Carru C, Caria MA, Tadolini B, Deiana L, Zinellu A: Acute variations in homocysteine levels are related to creatine changes induced by physical activity. Clin Nutr 2007;26:444-449.
3.
Tsubakihara Y, Hayashi T, Shoji T: Guanidinoacetic acid (GAA) in patients with chronic kidney disease (CKD) and diabetes mellitus (DM). Kidney Res Clin Pract 2012;31:A81.
4.
Ostojic SM, Niess B, Stojanovic M, Obrenovic M: Co-administration of methyl donors along with guanidinoacetic acid reduces the incidence of hyperhomocysteinaemia compared with guanidinoacetic acid administration alone. Br J Nutr 2013;110:865-870.
5.
Ostojic SM, Niess B, Stojanovic M, Obrenovic M: Creatine metabolism and safety profiles after six-week oral guanidinoacetic acid administration in healthy humans. Int J Med Sci 2013;10:141-147.
6.
Hiramatsu M: A role for guanidino compounds in the brain. Mol Cell Biochem 2003;244:57-62.
7.
Sestili P, Martinelli C, Bravi G, Piccoli G, Curci R, Battistelli M, Falcieri E, Agostini D, Gioacchini AM, Stocchi V: Creatine supplementation affords cytoprotection in oxidatively injured cultured mammalian cells via direct antioxidant activity. Free Radic Biol Med 2006;40:837-849.
8.
Sestili P, Barbieri E, Martinelli C, Battistelli M, Guescini M, Vallorani L, Casadei L, D'Emilio A, Falcieri E, Piccoli G, Agostini D, Annibalini G, Paolillo M, Gioacchini AM, Stocchi V: Creatine supplementation prevents the inhibition of myogenic differentiation in oxidatively injured C2C12 murine myoblasts. Mol Nutr Food Res 2009;53:1187-1204.
9.
Percário S, Domingues SP, Teixeira LF, Vieira JL, de Vasconcelos F, Ciarrocchi DM, Almeida ED, Conte M: Effects of creatine supplementation on oxidative stress profile of athletes. J Int Soc Sports Nutr 2012;9:56.
10.
Zugno AI, Scherer EB, Mattos C, Ribeiro CA, Wannmacher CM, Wajner M, Wyse AT: Evidence that the inhibitory effects of guanidinoacetate on the activities of the respiratory chain, Na+,K+-ATPase and creatine kinase can be differentially prevented by taurine and vitamins E and C administration in rat striatum in vivo. Biochim Biophys Acta 2007;1772:563-569.
11.
Zugno AI, Stefanello FM, Scherer EB, Mattos C, Pederzolli CD, Andrade VM, Wannmacher CM, Wajner M, Dutra-Filho CS, Wyse AT: Guanidinoacetate decreases antioxidant defenses and total protein sulfhydryl content in striatum of rats. Neurochem Res 2008;33:1804-1810.
12.
Sestili P, Martinelli C, Colombo E, Barbieri E, Potenza L, Sartini S, Fimognari C: Creatine as an antioxidant. Amino Acids 2011;40:1385-1396.
13.
Ostojic SM, Stojanovic M: Guanidinoacetic acid loading affects plasma γ-aminobutyric acid in healthy men. Eur J Nutr 2015;54:855-858.
14.
Hagfors L, Leanderson P, Sköldstam L, Andersson J, Johansson G: Antioxidant intake, plasma antioxidants and oxidative stress in a randomized, controlled, parallel, Mediterranean dietary intervention study on patients with rheumatoid arthritis. Nutr J 2003;2:5.
15.
Erel O: A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005;38:1103-1111.
16.
Mori A, Kohno M, Masumizu T, Noda Y, Packer L: Guanidino compounds generate reactive oxygen species. Biochem Mol Biol Int 1996;40:135-143.
17.
Orita Y, Tsubakihara Y, Ando A, Nakata K, Takamitsu Y, Fukuhara Y, Abe H: Effect of arginine or creatinine administration on the urinary excretion of methylguanidine. Nephron 1978;22:328-336.
18.
Lawler JM, Barnes WS, Wu G, Song W, Demaree S: Direct antioxidant properties of creatine. Biochem Biophys Res Commun 2002;290:47-52.
19.
Wang LS, Shi BM, Shan AS, Zhang YY: Effects of guanidinoacetic acid on growth performance, meat quality and antioxidation in growing-finishing pigs. J Anim Vet Adv 2012;11:631-636.
20.
Tachikawa M, Hosoya K: Transport characteristics of guanidino compounds at the blood-brain barrier and blood-cerebrospinal fluid barrier: relevance to neural disorders. Fluids Barriers CNS 2011;8:13.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.